The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy
Ying Zhang, V. Akhil, Ho Seong Seo, Hae‐Ran Park, Soo Hyun Kim, Sung-Hwan You, Zhipeng Liu, Soyoung Kim, Rukhsora D. Sultonova, Jung‐Joon Min, Yeongjin Hong
Abstract
CRT-specific L-ASNases are useful as additive drug candidates in tumors treated with RT, and combination treatment with anti-PD-L1 antibody increases their therapeutic efficacy.
Topics & Concepts
Immunogenic cell deathCalreticulinCancer researchImmune systemFlow cytometryTumor microenvironmentAntibodyCytotoxicityChemistryImmunotherapyMedicineImmunologyIn vitroEndoplasmic reticulumBiochemistryCancer Research and TreatmentsCancer Immunotherapy and BiomarkersCAR-T cell therapy research